<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

1   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

2   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

 

Discover the infinite power of partnership to drive scientific discovery

Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.

We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.

Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.

Latest News

Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner

Read More

Oncology Databases

Quickly Find Models to Fit Your Research Needs

Learn More

Learn more about our services

Therapeutic Areas

Leverage our extensive experience in oncology, immuno-oncology, immune-mediated inflammatory and cystopathic diseases

Learn More

Model Systems

Discover the largest commercially available collection of PDX models as well as our novelin vitro models

Learn More

Technologies

Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies

Learn More

Service Types

Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services

Learn More

Industry-leading Customer Experience

Data Below Represents Q4 2022

Studies <br>Completed

Studies
Completed

This data point indicates the total number of studies in Q4 2022 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.

Studies
Completed

1947

Customer <br>Satisfaction

Customer
Satisfaction

Also known as CSAT, this metric indicates how satisfied customer are with the complete Crown Bioscience customer experience.

Customer
Satisfaction

90%

Customer <br>Effort

Customer
Effort

The Customer Effort Score (CES) is a metric that measures how easy it was to work with Crown Bioscience.

Customer
Effort

96%

Customer <br>Expectation

Customer
Expectation

This metric indicates the strength of Crown Bioscience in meeting or exceeding customer expectations.

Customer
Expectation

92%

Review our published work!

DISCOVER MORE

Crown Bioscience is an expert preclinical CRO.

Learn More

Latest Resources

View All Resources

Latest Factsheet

Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services

Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services

View Factsheet ›

Latest Application Note

HCC827 NSCLC Cell Line Derived Xenograft Model

Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources

View Application Note ›

Latest Poster

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

View Poster ›

Latest Webinar

Matched Model Pairs and Patient-Derived Xenografts and Organoids Biobanks

Matched Model Pairs and Patient-Derived Xenografts and Organoids Biobanks

View Webinar ›

Latest Blog Posts

View All Posts

March 15, 2023

Are You Doing Proteomics Correctly for Xenografts?

Proteomic profiling is an important aspect of cancer research and drug development. It provides protein abundance information that complements genomics data from next-generation sequencing (NGS).

Read ›

March 3, 2023

Defining Organoids: Exploring Their True Characteristics and Practical Uses

The use of more clinically relevant preclinical models can help to reduce anticancer drug attrition rates by providing a better understanding of the safety, efficacy, and mechanism of a drug candidate, which can help inform downstream decisions.

Read ›

February 28, 2023

Accelerating Cancer Drug Development for Children and Adolescents

Significant progress has been made in the treatment of pediatric cancers, with the 5-year survival rate for children with cancer overall in high-income countries currently at ~80%. Despite this progress, there are still major unmet needs in this patient population. The 5-year survival rate for children with cancer in middle- and low-income countries are ~55% and ~40%, respectively, and survival prospects for several pediatric cancers are still very poor.

Read ›

February 16, 2023

Next-Generation Discovery Proteomics: The Power of Ion Mobility Mass Spectrometry with Data-Independent Acquisition

Next-generation discovery proteomics in preclinical and translational research is an exciting application of this proteomic approach. By leveraging advanced technologies, the ability to identify and quantify thousands of proteins in an unbiased manner can have a significant impact on the overall development of novel therapies.

Read ›

Ensuring that every patient has the right
treatment at the right time.